Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00661 |
| Species: | Homo sapiens |
| Position : | chr4:108226000-108228000 |
| Year: | 2021 |
| Title: | FOXP4 promotes laryngeal squamous cell carcinoma progression through directly targeting LEF1 |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | laryngeal squamous cell carcinoma |
| PMID: | 33793581 |
| MONDO: | MONDO:0005083 |
| Tissue: | Larynx |
| Tissue Ontology ID: | UBERON:0001737 |
| Cell Source: | TU177 |
| CVCL ID: | CVCL_4904 |
| Cell Type: | laryngeal squamous cell carcinoma cell |
| Cell Ontology ID: | CL:0000069 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR, qRT-PCR |
| Target gene : | LEF1 |
| TF name : | FOXP4 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|